Cargando…
Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors
Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that expresses the Philadelphia chromosome and constitutively activated Bcr-Abl tyrosine kinase in hematopoietic progenitor cells. Bcr-Abl tyrosine-kinase inhibitors (TKI) do not definitively cure all CML patients. The efficacy of T...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043757/ https://www.ncbi.nlm.nih.gov/pubmed/35493444 http://dx.doi.org/10.3389/fimmu.2022.840173 |
_version_ | 1784694952538669056 |
---|---|
author | de Almeida, Felipe Campos Berzoti-Coelho, Maria G. Toro, Diana Mota Cacemiro, Maira da Costa Bassan, Vitor Leonardo Barretto, Gabriel Dessotti Garibaldi, Pedro Manoel Marques Palma, Leonardo Carvalho de Figueiredo-Pontes, Lorena Lobo Sorgi, Carlos Arterio Faciolli, Lucia Helena Gardinassi, Luiz Gustavo de Castro, Fabíola Attié |
author_facet | de Almeida, Felipe Campos Berzoti-Coelho, Maria G. Toro, Diana Mota Cacemiro, Maira da Costa Bassan, Vitor Leonardo Barretto, Gabriel Dessotti Garibaldi, Pedro Manoel Marques Palma, Leonardo Carvalho de Figueiredo-Pontes, Lorena Lobo Sorgi, Carlos Arterio Faciolli, Lucia Helena Gardinassi, Luiz Gustavo de Castro, Fabíola Attié |
author_sort | de Almeida, Felipe Campos |
collection | PubMed |
description | Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that expresses the Philadelphia chromosome and constitutively activated Bcr-Abl tyrosine kinase in hematopoietic progenitor cells. Bcr-Abl tyrosine-kinase inhibitors (TKI) do not definitively cure all CML patients. The efficacy of TKI is reduced in CML patients in the blastic phase—the most severe phase of the disease—and resistance to this drug has emerged. There is limited knowledge on the underlying mechanisms of disease progression and resistance to TKI beyond BCR-ABL1, as well as on the impact of TKI treatment and disease progression on the metabolome of CML patients. The present study reports the metabolomic profiles of CML patients at different phases of the disease treated with TKI. The plasma metabolites from CML patients were analyzed using liquid chromatography, mass spectrometry, and bioinformatics. Distinct metabolic patterns were identified for CML patients at different phases of the disease and for those who were resistant to TKI. The lipid metabolism in CML patients at advanced phases and TKI-resistant patients is reprogrammed, as detected by analysis of metabolomic data. CML patients who were responsive and resistant to TKI therapy exhibited distinct enriched pathways. In addition, ceramide levels were higher and sphingomyelin levels were lower in resistant patients compared with control and CML groups. Taken together, the results here reported established metabolic profiles of CML patients who progressed to advanced phases of the disease and failed to respond to TKI therapy as well as patients in remission. In the future, an expanded study on CML metabolomics may provide new potential prognostic markers for disease progression and response to therapy. |
format | Online Article Text |
id | pubmed-9043757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90437572022-04-28 Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors de Almeida, Felipe Campos Berzoti-Coelho, Maria G. Toro, Diana Mota Cacemiro, Maira da Costa Bassan, Vitor Leonardo Barretto, Gabriel Dessotti Garibaldi, Pedro Manoel Marques Palma, Leonardo Carvalho de Figueiredo-Pontes, Lorena Lobo Sorgi, Carlos Arterio Faciolli, Lucia Helena Gardinassi, Luiz Gustavo de Castro, Fabíola Attié Front Immunol Immunology Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that expresses the Philadelphia chromosome and constitutively activated Bcr-Abl tyrosine kinase in hematopoietic progenitor cells. Bcr-Abl tyrosine-kinase inhibitors (TKI) do not definitively cure all CML patients. The efficacy of TKI is reduced in CML patients in the blastic phase—the most severe phase of the disease—and resistance to this drug has emerged. There is limited knowledge on the underlying mechanisms of disease progression and resistance to TKI beyond BCR-ABL1, as well as on the impact of TKI treatment and disease progression on the metabolome of CML patients. The present study reports the metabolomic profiles of CML patients at different phases of the disease treated with TKI. The plasma metabolites from CML patients were analyzed using liquid chromatography, mass spectrometry, and bioinformatics. Distinct metabolic patterns were identified for CML patients at different phases of the disease and for those who were resistant to TKI. The lipid metabolism in CML patients at advanced phases and TKI-resistant patients is reprogrammed, as detected by analysis of metabolomic data. CML patients who were responsive and resistant to TKI therapy exhibited distinct enriched pathways. In addition, ceramide levels were higher and sphingomyelin levels were lower in resistant patients compared with control and CML groups. Taken together, the results here reported established metabolic profiles of CML patients who progressed to advanced phases of the disease and failed to respond to TKI therapy as well as patients in remission. In the future, an expanded study on CML metabolomics may provide new potential prognostic markers for disease progression and response to therapy. Frontiers Media S.A. 2022-04-13 /pmc/articles/PMC9043757/ /pubmed/35493444 http://dx.doi.org/10.3389/fimmu.2022.840173 Text en Copyright © 2022 de Almeida, Berzoti-Coelho, Toro, Cacemiro, Bassan, Barretto, Garibaldi, Palma, de Figueiredo-Pontes, Sorgi, Faciolli, Gardinassi and de Castro https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology de Almeida, Felipe Campos Berzoti-Coelho, Maria G. Toro, Diana Mota Cacemiro, Maira da Costa Bassan, Vitor Leonardo Barretto, Gabriel Dessotti Garibaldi, Pedro Manoel Marques Palma, Leonardo Carvalho de Figueiredo-Pontes, Lorena Lobo Sorgi, Carlos Arterio Faciolli, Lucia Helena Gardinassi, Luiz Gustavo de Castro, Fabíola Attié Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors |
title | Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors |
title_full | Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors |
title_fullStr | Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors |
title_full_unstemmed | Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors |
title_short | Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors |
title_sort | bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043757/ https://www.ncbi.nlm.nih.gov/pubmed/35493444 http://dx.doi.org/10.3389/fimmu.2022.840173 |
work_keys_str_mv | AT dealmeidafelipecampos bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT berzoticoelhomariag bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT torodianamota bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT cacemiromairadacosta bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT bassanvitorleonardo bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT barrettogabrieldessotti bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT garibaldipedromanoelmarques bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT palmaleonardocarvalho bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT defigueiredoponteslorenalobo bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT sorgicarlosarterio bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT faciolliluciahelena bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT gardinassiluizgustavo bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors AT decastrofabiolaattie bioactivelipidsaschronicmyeloidleukemiaspotentialbiomarkersfordiseaseprogressionandresponsetotyrosinekinaseinhibitors |